Aqr Capital Management LLC Aeglea Bio Therapeutics, Inc. Transaction History

Aqr Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $18,393 - $97,853	-36,787 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $68,791 - $175,473	36,787 New	36,787 $85,000
Q4 2019 Feb 14, 2020	SELL	$7.23 - $8.55 $77,389 - $91,519	-10,704 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.42 - $9.0 $65,760 - $92,187	-10,243 Reduced 48.9%	10,704 $82,000
Q2 2019 Aug 14, 2019	SELL	$6.1 - $8.78 $44,835 - $64,532	-7,350 Reduced 25.97%	20,947 $143,000

Q3 2018 Nov 15, 2018	BUY	$8.24 - $11.0 $69,018 - $92,136	8,376 Added 42.05%	28,297 $271,000
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $156,778 - $216,939	19,921 New	19,921 $211,000

978K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.